Boviseal Dry Cow Intramammary Suspension
Country: Netherlands
Language: English
Source: HMA (Heads of Medicines Agencies)
Summary of Product characteristics
(SPC)
09-06-2013
Some documents for this product are not currently available, you can send a request to our customer service and we will notify you as soon as we are able to obtain them.
Send request.
Send request.
Active ingredient:
bismuth subnitrate 0 mg/ml
Available from:
Pfizer Limited
ATC code:
QG52X
Pharmaceutical form:
Intramammary suspension
Therapeutic group:
VARIOUS PRODUCTS FOR TEATS AND UDDER
Therapeutic area:
Cattle
Authorization date:
2012-07-25
Summary of Product characteristics
AN: 00369/2013
Revised: August 2013
Page 1 of 5
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Boviseal 2.6 g intramammary suspension for cattle (dairy cows).
Austria, Denmark and Germany - TEATSEAL 2.6 g intramammary suspension
for cattle (dairy cows).
Belgium - UBROXEAL 2.6 g intramammary suspension for cattle (dairy cows)
Italy, Luxembourg, Netherlands, Portugal, Spain - EASISEAL 2.6 g
intramammary suspension for cattle (dairy cows).
France - MAMISEAL 2.6 g intramammary suspension for cattle (dairy cows)
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each 4g intramammary syringe contains:
Active substance: Bismuth subnitrate, heavy
2.6g
For a full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Intramammary suspension
Greyish white, smooth, unctuous cream.
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Cattle (dairy cows).
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
Prevention of new intramammary infections throughout the dry period.
In cows considered likely to be free of sub-clinical mastitis, the product can be
used on its own in dry cow management and mastitis control.
Selection of cows for treatment with the product should be based on veterinary
clinical judgement. Selection criteria may be based on the mastitis and cell
count history of individual cows, or recognised tests for the detection of sub-
clinical mastitis or bacteriological sampling.
AN: 00369/2013
Revised: August 2013
Page 2 of 5
4.3
CONTRAINDICATIONS
See section 4.7. Do not use the product alone in c
Read the complete document
